William Karl Hornung Net Worth

Mr. William Karl Hornung biography

William Karl Hornung is the Chief Financial Officer at Diffusion Pharmaceuticals Inc.

What is the salary of Mr Hornung?

As the Chief Financial Officer of Diffusion Pharmaceuticals Inc, the total compensation of Mr Hornung at Diffusion Pharmaceuticals Inc is $409,868. There are 1 executives at Diffusion Pharmaceuticals Inc getting paid more, with Dr. Robert J. Cobuzzi Jr. having the highest compensation of $536,938.

How old is Mr Hornung?

Mr Hornung is 52, he's been the Chief Financial Officer of Diffusion Pharmaceuticals Inc since . There are 2 older and 2 younger executives at Diffusion Pharmaceuticals Inc. The oldest executive at Diffusion Pharmaceuticals Inc is Dr. David Randolph Jones M.D., 58, who is the Sr. Medical Advisor.

What's Mr Hornung's mailing address?

William's mailing address filed with the SEC is 300 E. MAIN ST. SUITE 201, , CHARLOTTESVILLE, VA, 22902.

Insiders trading at Diffusion Pharmaceuticals Inc

Over the last 9 years, insiders at Diffusion Pharmaceuticals Inc have traded over $0 worth of Diffusion Pharmaceuticals Inc stock and bought 61,786 units worth $39,139 . The most active insiders traders include Robert Joseph Jr. Cobuzzi, Isaac Blech a Jane H Hollingsworth. On average, Diffusion Pharmaceuticals Inc executives and independent directors trade stock every 60 days with the average trade being worth of $26,721. The most recent stock trade was executed by Diana M Lanchoney on 30 June 2023, trading 232 units of DFFN stock currently worth $1,021.

What does Diffusion Pharmaceuticals Inc do?

diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but

Diffusion Pharmaceuticals Inc executives and stock owners

Diffusion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Dr. Robert J. Cobuzzi Jr.,
  Pres, CEO & Director
• William Karl Hornung,
  Chief Financial Officer
• Dr. Christopher D. Galloway M.D.,
  Chief Medical Officer
• William Robert Elder J.D.,
  Gen. Counsel & Corp. Sec.
• Dr. Jennifer Llewelyn Ph.D.,
  Sr. Director & Head of CMC
• Suzanne Cassidy,
  Sr. Director & Head of Quality Assurance
• Brian D. Bollwage,
  Sr. Consultant - Regulatory Affairs
• Douglas Gravatt,
  Sr. Consultant for Manufacturing
• Harry Cook,
  VP of Clinical Operations
• Kelly Hoy,
  Director of Project Management
• Dr. David Randolph Jones M.D.,
  Sr. Medical Advisor
• William Karl Hornung,
  Chief Financial Officer
• Mark T Giles,
  Director
• John Gainer,
  Chief Scientific Officer
• Robert R Ruffolo,
  Director
• David G Kalergis,
  Chairman and CEO
• Robert W Adams,
  Director
• Thomas E Byrne,
  General Counsel
• Alan G Levin,
  Director
• Isaac Blech,
  Director
• Ben Shealy,
  Senior Vice President Finance
• Jane H Hollingsworth,
  Director
• Robert Joseph Jr. Cobuzzi,
  President & CEO
• Eric Francois,
  Director
• William Robert Elder,
  GC & Secretary
• Christopher D Galloway,
  Chief Medical Officer
• Diana M Lanchoney,
  Director
• Raven Jaeger,
  Chief Regulatory Officer